Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2000 January-February;48(1-2) > Minerva Cardioangiologica 2000 January-February;48(1-2):9-18

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

ORIGINAL ARTICLES  


Minerva Cardioangiologica 2000 January-February;48(1-2):9-18

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: English, Italian

Prospects of prostanoid therapy. Preliminary results

Castagno P. L., Di Molfetta L., Merlo M., Barile G., Violato F., Buzzacchino A., Ponzio F.


PDF  


Background. To evaluate the efficacy of treatment with prostaglandins (Iloprost and Alprostadil) in patients with peripheral artherial disease in whom a surgical act or a redo operation is not proposable and to set the role of these drugs in the therapy of arterial diseases.
Methods. We analyzed the results of 96 treatments in patients with peripheral artherial diseases of different etiology, treated in the Day Hospital in the Division of Vascular Surgery from the 1/1/1993 to the 30/6/1998. The efficacy of the treatment has been evaluated on the basis of the clinical picture (healing or reduction of ulcers, reduction of rest-pain, improvement of the ability to walk).
Results. We had positive results in 60% of the patients who completed the treatment, a good outcome for patients with particularly severe arterial disease. Interruptions induced by the occurrence of uncontrolled side-effects are a few (6.25%). Better results have been found in a special category of desease (arterial diseases not associated with diabetes, not very advanced clinical picture, female gender). Iloprost proved to be superior to Alprostadil.
Conclusions. Prostaglandins today represent an effective therapeutic solution to be considered. Further studies need to be done to find a category of patients who can have the best benefit from this kind of drug.

top of page

Publication History

Cite this article as

Corresponding author e-mail